

Product Name: Guanethidine Sulfate
Revision Date: 01/10/2021

Product Data Sheet

Guanethidine Sulfate

Cat. No.: A8443

CAS No.: 60-02-6


Formula: C20H44N8·H2O4S

M.Wt: 494.7

Synonyms:

Target: Others
Pathway: Others

Storage: Store at -20°C



Solvent & Solubility

insoluble in DMSO; insoluble in EtOH; ≥159.4 mg/mL in H2O

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.0214 mL	10.1071 mL	20.2143 mL
	5 mM	0.4043 mL	2.0214 mL	4.0429 mL
	10 mM	0.2021 mL	1.0107 mL	2.0214 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Antihypertensive compound		
IC ₅₀ & Target			
In Vitro	Cell Viability Assay		
	Cell Line:	the electrically stimulated mouse vas deferens	
	Preparation method:	This compound is soluble in DMSO. General tips for obtaining a higher	
		concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in	
		the ultrasonic bath for a while. Stock solution can be stored below -20°C for	
		several months.	
	Reacting conditions:	3 µM	

	Applications:	In the electrically stimulated mouse vas deferens, Guanethidine sulfate			
		inhibited twitching by 95%±3% in 15 min, but this effect was only partially			
		reversed after 1 h of washing (33%±12% of control).			
	Animal experiment				
In Vivo	Animal models:	Myocardial infarction (MI) rat model			
	Dosage form:	low-dose [LG], 1 mg/kg/day; medium-dose, 3 mg/kg/day; high-dose, 10			
	OE CONTRACTOR	mg/kg/day; administered via an osmotic mini-pump for 4 weeks			
	Applications:	In myocardial infarction (MI) rats, LG suppressed left ventricular (LV) dilation			
		(9.2±0.9 mm vs.11.0±0.8 mm) and improved LV fractional shortening			
		(25.0±4.5% vs. 16.4±4.7%) in association with a reduction of plasma NE levels			
		(520±250 pg/ml vs.1,000±570 pg/ml). Low-dose guanethidine reduced 24-h			
		(6%) and 28-day mortality (6%). High-dose guanethidine also reduced 24-h			
		mortality (12%) but increased 28-day mortality (91%).			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may			
	810	slightly differ with the theoretical value. This is caused by an experimental			
	OE	system error and it is normal.			

Product Citations

1. Turner T, Chen X, et al. "FGF21 increases water intake, urine output and blood pressure in rats." PLoS One. 2018 Aug 14;13(8):e0202182.PMID:30106981

See more customer validations on www.apexbt.com.

References

- [1]. Joyce PI1,Rizzi D,Caló G,Rowbotham DJ,Lambert DG. The effect of guanethidine and local anesthetics on the electrically stimulated mouse vas deferens. Anesth Analg. 2002 Nov;95(5):1339-43, table of contents.
- [2]. Igawa A1, Nozawa T, Fujii N, et al. Long-term treatment with low-dose, but not high-dose, guanethidine improves ventricular function and survival of rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2003 Aug 6;42(3):541-8.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE BIO

APE BIO

APE BIO

APE BIO

APE BIO

APE BIO